# Alterity Therapeutics (ATHE) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/ATHE
## Company Profile
- Ticker: ATHE
- Exchange: NASDAQ
- Sector: Biopharma
- Location: Australia and listed in the U
- Tags: CNS
## Stock Data
- Close: 4.51 USD
- Market cap: 1457306.2799999998 USD
- Last updated: 2026-09-08
## Business Overview
Alterity Therapeutics is a neuroscience company focused on neurodegenerative disease, especially disorders with alpha-synuclein pathology. Its story is built around trying to address difficult CNS diseases through disease-modifying biology.
## Why The Stock Is Moving

As of Sep 8, 2026, ATHE closed down 0.66% at $4.51. No new same-company headline was identified in the current news window.

## Geographic Base

Alterity is headquartered in Australia and listed in the U.S. market. It sits in small-cap neuroscience biotechnology.

## Business Model

The company depends on translational validation, clinical progress, and capital support. Investors usually watch early data and whether the biology can create a compelling neurodegeneration thesis.

## Landscape Position

Alterity occupies a specialized neurodegeneration niche within biotech. It is catalyst-sensitive because the market needs evidence that the platform can matter in CNS disease.

## Future Catalysts

- Alterity’s catalysts are ATH434 and the neurodegeneration / iron-biology story, with any clinical update that can re-rate the name quickly. The company is still very much a proof-of-concept story.

## Recent News
- 2026-09-03 11:05 EST — [Alterity Therapeutics to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026](https://biopharmsignal.com/news/ATHE/alterity-therapeutics-to-participate-in-a-fireside-chat-at-the-cantor-global-hea-8a0f08fc) — Source: Alterity Therapeutics
- 2026-08-12 11:05 EST — [Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434](https://biopharmsignal.com/news/ATHE/alterity-therapeutics-announces-granting-of-new-u-s-composition-of-matter-patent-be4620cf) — Source: Alterity Therapeutics
- 2026-08-06 11:25 EST — [Alterity Therapeutics to Present at the 46th Annual Canaccord Genuity Growth Conference](https://biopharmsignal.com/news/ATHE/alterity-therapeutics-to-present-at-the-46th-annual-canaccord-genuity-growth-con-320e768e) — Source: Alterity Therapeutics
- 2026-07-30 11:25 EST — [Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update](https://biopharmsignal.com/news/ATHE/alterity-therapeutics-releases-appendix-4c-q4-fy26-quarterly-cash-flow-report-co-536052cb) — Source: Alterity Therapeutics
- 2026-07-21 11:25 EST — [Alterity Therapeutics to Participate in the Virtual BTIG Biotechnology Conference 2026](https://biopharmsignal.com/news/ATHE/alterity-therapeutics-to-participate-in-the-virtual-btig-biotechnology-conferenc-5aaa51f2) — Source: Alterity Therapeutics